Clinical trial · Interventional
18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer
A Feasibility Study of Hypoxia Imaging in Patients With Lung Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to look for low levels of oxygen (hypoxia) in lung cancer using a positron emission tomography (PET) scan. Hypoxia can influence how lung cancer grows and responds to treatments like radiotherapy and chemotherapy. The use of PET scans to measure hypoxia may be better and simpler than the approaches used previously. This study will assess whether or not PET scans can provide useful information about hypoxia in lung cancer. In this study, a radiotracer called Fluoroazomycin Arabinoside (FAZA) will be used to measure hypoxia in the patient's tumour. FAZA has already been used in many cancers including lung cancer. Patients who consent to participate in this trial will receive 1 FAZA PET Scan prior to their first radiotherapy treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18-F-FAZA | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18-F-FAZA Scan
- description
- All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
- interventionNames
- Biological: 18-F-FAZA
Primary outcomes (2)
- measure
- Number of patients with lung cancer using the PET tracer FAZA to image primary tumor hypoxia prior to treatment with radiotherapy
- timeFrame
- 5 years
- measure
- Number of patients with lung cancer using 4D (gated) and static PET imaging of FAZA uptake
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years 2. Patients with stage II or III lung cancer (both NSCLC and SCLC) qualifying for radiotherapy to the primary tumor, with or without treatment of mediastinal or hilar lymph nodes 3. Intention to treat using radiotherapy according to the current treatment policies of the PMH Lung Group 4. Concurrent systemic therapy allowed 5. A negative serum pregnancy test within the two week interval immediately prior to PET-CT imaging, in women of child-bearing age 6. Ability to provide written informed consent to participate in the study Exclusion Criteria: 1. Previous radiotherapy to intended treatment volumes. 2. Previous systemic therapy 3. Active malignancy other than lung cancer 4. Unable to remain supine for more than 60 minutes 5. Pregnancy 6. Age less than 18 years old 7. Failure to provide written informed consent
References
Publications (0)
Data not yet available